Bioventus Inc. (BVS)

3.9800 -0.0900 (-2.21%) At close: 04:00PM EDT

Bioventus Inc.

4721 Emperor Boulevard
Suite 100
Durham, NC 27703
United States
919 474 6700
https://www.bioventus.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 970

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark L. Singleton	Senior VP & CFO	444.12k	N/A	1970
Mr. Robert Claypoole	President, CEO & Director	N/A	N/A	1972
Mr. Mike Crowe B.S., M.B.A.	Senior Vice President of Operations	N/A	N/A	N/A
Mr. David Crawford	Vice President of Investor Relations & Treasurer	N/A	N/A	N/A
Mr. Anthony D'Adamio	Senior VP, General Counsel & Corporate Secretary	618.29k	N/A	1961
Ms. Katrina J. Church J.D.	Senior VP & Chief Compliance Officer	N/A	N/A	1962
Ms. Helen Leupold	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A
Mr. Larry Chen	Managing Director of China & Asia Pacific	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Corporate governance

Bioventus Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.